|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the ABII 10-K filed Mar 12, 2010. Acquired in-Process Research and Development In connection with the purchase of Shimoda Biotech and Platco Technologies in April 2008, we acquired certain research and development projects that were required to be expensed in accordance with generally accepted accounting principles. Approximately $13.9 million of the purchase price was expensed as in-process research and development for projects that, as of the acquisition date, had not yet reached technological or regulatory feasibility and had no alternative future uses in their current states. Acquired In-Process Research and Development For acquisitions prior to January 1, 2009, the estimated fair value of acquired in-process research and development projects, which had not reached technological feasibility at the date of acquisition and which did not have an alternative future use, were immediately expensed. Beginning January 1, 2009, newly issued accounting standards require that the fair value of acquired in-process research and development projects acquired in a business combination be capitalized at the acquisition date. These excerpts taken from the ABII 10-K filed Mar 6, 2009. Acquired in-Process Research and Development In connection with the purchase of Shimoda Biotech and Platco Technologies in April 2008, we acquired certain research and development projects that were required to be expensed in accordance with generally accepted accounting principles. Approximately $13.9 million of the purchase price was expensed as in-process research and development for projects that, as of the acquisition date, had not yet reached technological or regulatory feasibility and had no alternative future uses in their current states.
43
Table of ContentsThe $83.4 million of in-process research and development in 2006 resulted from the 2006 Merger. Research and development activities that had not yet reached technological or regulatory feasibility and had no alternative future use in their current state at the merger date were expensed. Acquired In-Process Research and Development For acquisitions prior to January 1, 2009, the estimated fair value of acquired in-process research and development projects, which had not reached technological feasibility at the date of acquisition and which did not have an alternative future use, were immediately expensed. Beginning January 1, 2009, with the adoption of FASB Statement No. 141R, Business Combination, the fair value of acquired in-process research and development projects will be capitalized at acquisition date (see “Recent Accounting Pronouncements” below. Acquired For acquisitions prior to January 1, 2009, the estimated fair value of acquired in-process We This excerpt taken from the ABII 10-Q filed Nov 14, 2008. Acquired In-Process Research and Development In connection with the purchase of Shimoda Biotech and Platco Technologies in April 2008, we acquired certain research and development projects that were required to be expensed in accordance with generally accepted accounting principles. Approximately $13.9 million of the purchase price was expensed as in-process research and development for projects that, as of the acquisition date, had not yet reached technological or regulatory feasibility and had no alternative future uses in their current states. This excerpt taken from the ABII 10-Q filed Aug 14, 2008. Acquired In-Process Research and Development In connection with the purchase of Shimoda Biotech and Platco Technologies in April 2008, we acquired certain research and development projects that were required to be expensed in accordance with generally accepted accounting principles. Approximately $13.9 million of the purchase price was expensed as in-process research and development for projects that, as of the acquisition date, had not yet reached technological or regulatory feasibility and had no alternative future uses in their current states. | EXCERPTS ON THIS PAGE:
|
| |||||||
